Bristol Myers Squibb Says Zeposia Analyses Show Benefits in Relapsing Multiple Sclerosis Treatment
June 24 2022 - 1:41PM
Dow Jones News
By Denny Jacob
Bristol Myers Squibb said Friday new analyses from two Phase 3
trials of Zeposia showed early use of the treatment demonstrated
cognitive benefits in people with relapsing multiple sclerosis, a
disease in which the immune system attacks the protective covering
of nerves.
The biopharmaceutical product developer said the greatest effect
from the demonstrated cognitive benefits were seen in people with
high thalamic volume, supporting an association between preserved
brain volume and improved long-term cognitive outcomes.
Zeposia was well tolerated with more than 80% of people who
started the Phase 3 SUNBEAM trial remaining on continuous therapy
through 48 months of the Phase 3 DAYBREAK OLE study, Bristol Myers
Squibb said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 24, 2022 13:26 ET (17:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
